Stefan Aigner

Investor in Direct Allergy and Advisor to Direct Allergy Management Team – Stefan Aigner, MD has more than twenty years of broad healthcare industry experience. He also is a co-founder and Chief Executive Officer of Inspirion Pharmaceuticals LLC, a specialty pharmaceutical company committed to “provide physicians and patients options to help battle the growing societal epidemic of prescription drug abuse“. Dr. Aigner was previously Executive Vice President of Corporate and Business Development at Alpharma, Inc., where he was responsible for transforming the company’s specialty pharmaceuticals business precipitating its acquisition by King Pharmaceuticals for $1.6 billion in 2008.

Prior to Alpharma, Dr. Aigner was co-founder of Reliant Pharmaceuticals, Inc., a private equity backed specialty pharmaceutical company. During his seven-year tenure at Reliant, Dr. Aigner was a key driver in building a fully integrated specialty pharma infrastructure with more than 1,300 employees. He held the position of Executive Vice President of Business Development and Scientific Affairs and led the company through multiple product acquisitions and in-licensing transactions with aggregate deal value in excess of $1 billion. He was also part of the management team that successfully raised over $750 million in multiple private equity and venture capital funding rounds. Reliant was acquired by GlaxoSmithKlinein 2007 for $1.65 billion. Prior to co-founding Reliant, Dr. Aigner was a Senior Consultant with The Wilkerson Group, a specialty healthcare consulting firm in New York.

Dr. Aigner is a Chartered Financial Analyst (CFA) and has over ten years of broad clinical experience including four years of postgraduate OB/GYN experience at Mt. Sinai Medical Center in New York. He is a member of the Board of Directors of Cipher Pharmaceuticals and several privately held companies.

Dr. Aigner graduated summa cum laude with a medical degree from the Unive